Stock comparison
Corcept Therapeutics
Eli Lilly
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
CORT
Corcept Therapeutics
Market cap
$6.34B
Sector
Healthcare
LLY
Eli Lilly
Market cap
$974.4B
Sector
Healthcare
Overall winner
Eli Lilly LLY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | CORT | LLY | Winner |
|---|---|---|---|
| Warren Buffett | 68D | 72B | LLY |
| Benjamin Graham | 86C | 86A | Tie |
| Philip Fisher | 64C | 86A | LLY |
| Peter Lynch | 32F | 74B | LLY |
| Joel Greenblatt | 47D | 78C | LLY |
| Charlie Munger | 60C | 85A | LLY |
| Terry Smith | 68C | 77C | LLY |
Side-by-side metrics
| Metric | CORT | LLY |
|---|---|---|
| Market cap | $6.34B | $974.4B |
| P/E (TTM) | 122.0x | 36.6x |
| EV/EBIT | 131.9x | 34.1x |
| ROIC (TTM) | -1.23% | 32.06% |
| Gross margin | 98.25% | 83.51% |
| Net margin | 6.23% | 34.98% |
| Revenue CAGR 5y | 20.1% | 23.17% |
| EPS CAGR 5y | -0.52% | 40.81% |
| Debt / Equity | 0.0x | 1.4x |
| Dividend yield | 0.0% | 0.62% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
CORT leads on
- Debt / Equity0.0xvs 1.4x+99%
- Gross margin98.25%vs 83.51%+15%
LLY leads on
- ROIC (TTM)32.06%vs -1.23%+104%
- EPS CAGR 5y40.81%vs -0.52%+101%
- Dividend yield0.62%vs 0.0%+100%
- Market cap$974.4Bvs $6.34B+99%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.